Stoke Therapeutics (NASDAQ:STOK) Shares Down 4.7%

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price traded down 4.7% during trading on Monday . The company traded as low as $13.06 and last traded at $13.11. 114,268 shares were traded during mid-day trading, a decline of 86% from the average session volume of 805,699 shares. The stock had previously closed at $13.75.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on STOK shares. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Wedbush reissued an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Trading Down 3.5 %

The firm has a market capitalization of $691.65 million, a price-to-earnings ratio of -5.56 and a beta of 0.96. The business has a 50-day moving average price of $14.50 and a two-hundred day moving average price of $13.21.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. The firm had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now owns 2,485 shares in the company, valued at approximately $34,168.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 11.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its stake in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after buying an additional 1,038 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Stoke Therapeutics by 5.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock valued at $425,000 after purchasing an additional 1,642 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the last quarter. Quest Partners LLC bought a new position in shares of Stoke Therapeutics in the second quarter valued at $29,000. Finally, Los Angeles Capital Management LLC lifted its position in shares of Stoke Therapeutics by 7.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after acquiring an additional 4,508 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.